FGF19 and metabolic disease: Although FGF19 is used to treat metabolic diseases such as nonalcoholic steatohepatitis and diabetes,[35] one study indicated that FGF19 has both lipid‐raising and lipid‐lowering effects that may be mediated by different FGF receptors and target tissues.[36] Our findings reveal that FGF19 activates HSCs in the CRCLM models, which may warrant further investigation into the use of FGF19 analog to treat metabolic diseases in cancer patients.